279 related articles for article (PubMed ID: 9862830)
1. Glucagon-like peptide-1: a potent regulator of food intake in humans.
Gutzwiller JP; Göke B; Drewe J; Hildebrand P; Ketterer S; Handschin D; Winterhalder R; Conen D; Beglinger C
Gut; 1999 Jan; 44(1):81-6. PubMed ID: 9862830
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
[TBL] [Abstract][Full Text] [Related]
3. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
[TBL] [Abstract][Full Text] [Related]
4. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
Chelikani PK; Haver AC; Reidelberger RD
Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
[TBL] [Abstract][Full Text] [Related]
5. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
[TBL] [Abstract][Full Text] [Related]
6. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
Gutzwiller JP; Drewe J; Göke B; Schmidt H; Rohrer B; Lareida J; Beglinger C
Am J Physiol; 1999 May; 276(5):R1541-4. PubMed ID: 10233049
[TBL] [Abstract][Full Text] [Related]
8. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.
Gutzwiller JP; Degen L; Matzinger D; Prestin S; Beglinger C
Am J Physiol Regul Integr Comp Physiol; 2004 Sep; 287(3):R562-7. PubMed ID: 15105167
[TBL] [Abstract][Full Text] [Related]
9. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men.
Brennan IM; Feltrin KL; Horowitz M; Smout AJ; Meyer JH; Wishart J; Feinle-Bisset C
Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1477-85. PubMed ID: 15695321
[TBL] [Abstract][Full Text] [Related]
11. Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.
Melhorn SJ; Tyagi V; Smeraglio A; Roth CL; Schur EA
Appetite; 2014 Nov; 82():85-90. PubMed ID: 25049134
[TBL] [Abstract][Full Text] [Related]
12. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
[TBL] [Abstract][Full Text] [Related]
13. Effect of peptide YY3-36 on food intake in humans.
Degen L; Oesch S; Casanova M; Graf S; Ketterer S; Drewe J; Beglinger C
Gastroenterology; 2005 Nov; 129(5):1430-6. PubMed ID: 16285944
[TBL] [Abstract][Full Text] [Related]
14. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
15. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
16. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
17. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.
Lugari R; Dei Cas A; Ugolotti D; Finardi L; Barilli AL; Ognibene C; Luciani A; Zandomeneghi R; Gnudi A
Horm Metab Res; 2002 Mar; 34(3):150-4. PubMed ID: 11972305
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
Dupre J; Behme MT; Hramiak IM; McFarlane P; Williamson MP; Zabel P; McDonald TJ
Diabetes; 1995 Jun; 44(6):626-30. PubMed ID: 7789625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
